tri agonist glp 1 retatrutide triple glp-1 gip glucagon phase 3 2025 Retatrutide What GLP‑3 Really Is: Retatrutide

82,83 Animal studies have demonstrated the protective effects of DPP4 inhibitors in IBD

Front Endocrinol (Lausanne) 2024;15 doi: 10.3389/fendo.2024.1431292

By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide

Physiological Reviews , 87(4), 14091439

Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes

Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: Data from the international SWEET registry